Most Popular Products
Ruxolitinib Phosphate
3.6 USD ($)/Gram
Product Details:
- Shelf Life 36 Months
- Melting Point 84-89
- Taste Other
- Molecular Formula C17H21N6O4P
- Loss on Drying Not more than 0.5%
- Smell Other
- HS Code 2933599099
- Click to View more
X
Ruxolitinib Phosphate Price And Quantity
- 3.6 USD ($)/Gram
- 1 Gram
Ruxolitinib Phosphate Product Specifications
- White to almost white powder
- Other
- 1092939-17-7
- 98.0% ~ 102.0%
- Ruxolitinib has the following main effects: 1. MPN treatment: Ruxolitinib is widely used to treat MPN, including diseases such as chronic myeloid leukemia and primary myelofibrosis. It helps control the proliferation of abnormal bone marrow cells and relieves related symptoms. 2. Rheumatoid arthritis treatment: In some RA patients, ruxolitinib can relieve arthritis symptoms and improve quality of life, especially for those who are insensitive to or intolerant of traditional anti-rheumatic drugs. The drug has performed well in clinical trials, with significant efficacy and high safety. Ruxolitinib is a drug commonly used to treat myelofibrosis, polycythemia vera, and acute graft-versus-host disease refractory to corticosteroids. Its unique mechanism of action helps patients relieve symptoms and improve quality of life, bringing good news to many patients. 1. Therapeutic effect of myelofibrosis: Myelofibrosis is a bone marrow disease characterized by the proliferation of fibroblasts in the bone marrow, accompanied by fibrin deposition and destruction of hematopoietic tissue. Ruxolitinib phosphate can reduce the fibrotic reaction by inhibiting the activity of Janus kinase, thereby alleviating the symptoms of patients with myelofibrosis and delaying the progression of the disease. 2. Therapeutic effect of polycythemia vera: Polycythemia vera, also known as primary polycythemia vera, is a myeloproliferative disease in which the patient has too many red blood cells. Ruxolitinib can regulate the hematopoietic process by affecting the proliferation and differentiation pathways of stem cells, help control the number of red blood cells, and alleviate symptoms and complications. 3. Efficacy of corticosteroid-refractory acute graft-versus-host disease: In the treatment of corticosteroid-refractory acute graft-versus-host disease, ruxolitinib phosphate can inhibit the activity of T cells, reduce immune response, reduce the rejection reaction and complications after allogeneic hematopoietic stem cell transplantation, and improve the treatment effect.
- Not more than 0.5%
- 2.5 ~ 4.5
- Ruxolitinib Phosphate
- C17H21N6O4P
- Other
- (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
- Other
- 84-89
- 404.360201
- Powder
- Ruxolitinib phosphate is soluble in water and some common organic solvents (such as DMSO or ethanol).
- Room Temperature
- 1312995-182-4
- 2933599099
- 36 Months
- Medicine Grade
Ruxolitinib Phosphate Trade Information
- Shanghai, Beijing, Shenzhen or Dongguan
- Paypal Letter of Credit at Sight (Sight L/C) Telegraphic Transfer (T/T) Western Union
- 50000 Gram Per Month
- 5 Days
- Yes
- If order is confirmed we will reimburse the sample cost
- 10g/Bag, 20g/Bag, 50g/Bag, 100g/Bag, 500g/Bag, 1kg/Bag or according to the specific requirements from customers.
- Australia North America South America Eastern Europe Western Europe
Product Description
Ruxolitinib Phosphate is the phosphate form of Ruxolitinib, which is a tyrosine kinase inhibitor and is mainly used clinically to treat myeloproliferative neoplasms such as chronic myeloid leukemia and myelofibrosis.Tell us about your requirement
Price:
Quantity
Select Unit
- 50
- 100
- 200
- 250
- 500
- 1000+
Additional detail
Mobile number
Email
Other Products in 'APIs And Intermediates' category
Quick Inquiry
Contact Details
DALIAN HANDOM CHEMICALS CO.,LTD.
RM702, Unit 1, Building 21, Liuhe Road, Ganjingzi Dist,Dalian - 116091, Liaoning, China
Phone :--+8615840669648
Send InquiryE-mail us : export@handom-chem.com
 |
DALIAN HANDOM CHEMICALS CO.,LTD.
All Rights Reserved.(Terms of Use) Developed and Managed by Infocom Network Private Limited. |
